Group B Streptococcus Clinical Trial
Official title:
Membrane Sweeping in GBS Positive Patients at 37 Weeks Gestation: A Randomized Controlled Trial
Sweeping or stripping of the membranes (in this paper referred to as "membrane sweeping") is
a widely utilized technique to hasten delivery for women at 37+ weeks gestation. The process
of membrane sweeping probably causes release of prostaglandins from the decidua and the
cervix. The efficacy of membrane sweeping is well studied, and has been shown to increase
the number of patients in labor within 72 hours, reduce the frequency of pregnancy
continuing beyond 41 or 42 weeks, and reduce the frequency of formal induction of labor.
Thus, it is a safe and practical option for women who wish to avoid inductions of labor or
postterm pregnancies.
Group B streptococcus (GBS; streptococcus agalactiae) is a gram positive coccus that
frequently colonizes the human genital tract. In pregnant women, GBS can cause urinary tract
infections, chorioamnionitis, and postpartum endometritis. Newborn infants can also acquire
GBS infection during passage through the vagina. Early onset GBS disease in the newborn can
lead to pneumonia, meningitis, and sepsis, all of which can be life-threatening. Early onset
GBS disease has become rare since the widespread use of GBS screening and prophylactic
treatment of pregnant women.
The relationship between early onset GBS disease and sweeping of the membranes is not known.
Based on the theoretical increased risk of bacterial seeding after membrane sweeping, as
well as concern for fast labors and inadequate treatment after membrane sweeping, some
practitioners choose not to sweep membranes in GBS positive patients. A meta-analysis did
not show a difference in neonatal or maternal infection rates between women who underwent
membrane sweeping and those who did not. ACOG guidelines state "the risks of membrane
stripping in GBS positive patients has not been investigated in well-designed, prospective
studies. Therefore, data are insufficient to encourage or discourage this practice".
Specific Aims:
In order to help elucidate the effect of membrane sweeping in GBS positive patients, the
investigators propose this prospective randomized trial. The investigators primary objective
is to determine whether membrane sweeping in GBS positive women is associated with
inadequate antibiotic treatment in labor (defined as less than four hours of antibiotic
therapy prior to delivery). The investigators secondary objectives are to measure the effect
of membrane sweeping on pregnancy duration, length of labor and adverse events potentially
related to membrane sweeping such as maternal chorioamnionitis and neonatal morbidity.
Randomization is the real research portion of this study, since offering membrane sweeping
is already the standard of care. Patients are followed until the time of delivery, which is
within 6 weeks of enrollment for most women.
n/a
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04059510 -
Developing a Controlled Human Infection Model for Group B Streptococcus (CHIM_GBS)
|
||
Completed |
NCT01150123 -
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women
|
Phase 1 | |
Completed |
NCT02511444 -
Intrapartum Rapid GBS Testing in Patients Presenting With Threatened Preterm Labor
|
N/A | |
Completed |
NCT00716781 -
Management of Infants Born to Group B Streptococcus Positive Mothers.
|
N/A | |
Completed |
NCT01982084 -
Group B Streptococcus: Attitudes to Immunisation in Pregnancy
|
||
Active, not recruiting |
NCT00972894 -
Group B Streptococcus (GBS) Polymerase Chain Reaction (PCR) Concordance Study
|
N/A | |
Terminated |
NCT00823433 -
Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood
|
Phase 0 | |
Completed |
NCT01251289 -
The Prevalence of Group B Streptococcus Positive Pregnant Patients in an Inner City Tertiary Care Center
|
||
Completed |
NCT00008853 -
Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines
|
Phase 1 |